Infectious Disease Epidemiology

Andrew Lover

Andrew Lover

Assistant Professor of Epidemiology

UMass-Amherst

Biography

Andrew Lover is an assistant professor of epidemiology in the School of Public Health and Health Sciences, at UMass-Amherst. His research covers a broad range of infectious disease epidemiology, including tick-borne disease; surveillance and forecasting; malaria; and the design, implementation, and analysis of complex epidemiological studies, in both domestic (Western Massachusetts) and global contexts (including Vietnam, Lao PDR, Timor-Leste, and Cambodia).

SARS-CoV-2/COVID-19: he is currently supporting global efforts to slow the spread of this pandemic. This work includes a faculty role in the Academic Public Health Volunteer Corps; syndromic surveillance and modeling studies; and implementation of a large-scale serological survey (“antibody test”) across Massachusetts. This study (Sero-Mass) is expected to enroll 2,000 participants across the Commonwealth in early Spring 2020.

His lab currently consists of two PhD students (Estee Cramer and Teah Snyder) and three MS/MPH students (Ashley Moineau, Johanna Ravenhurst, and Gabri Silverman); their studies involve a combination of qualitative and quantitative field data collection, quantitative analysis, and modeling to directly inform public health policy.

Interests

  • Infectious disease surveillance (pathogens, serology and vectors)
  • Interventional trials
  • Global health
  • Vector-borne disease

Education

  • Research Fellow, 2018

    University of California, San Francisco

  • PhD in Epidemiology, 2015

    National University of Singapore

  • MPH in Epidemiology and Global Health, 2011

    National University of Singapore

  • MS in Organic Chemistry, 2003

    University of California, Santa Barbara

  • BA in Chemistry, 1997

    Earlham College

Recent and Upcoming Talks

Recent Publications

Quickly discover relevant content by filtering publications.

Quantifying treatment effects of hydroxychloroquine and azithromycin for COVID-19: a secondary analysis of an open label non-randomized clinical trial (Gautret et al, 2020)

Abstract: NB: The author stands by all analytical and statistical aspects of this preprint. However, subsequent to this analysis, further details of the original study have been released- with major uncertainties in study design, reporting, choice of endpoints, and most importantly, data integrity [1, 2].

Sentinel Event Surveillance to Estimate Total SARS-CoV-2 Infections, United States

Abstract: Human infections with a novel coronavirus (SARS-CoV-2) were first identified via syndromic surveillance in December of 2019 in Wuhan China. Since identification, infections (coronavirus disease-2019; COVID-19) caused by this novel pathogen have spread globally, with more than 180,000 confirmed cases as of March 16, 2020.

The impact of transfluthrin on the spatial repellency of the primary malaria mosquito vectors in Vietnam: Anopheles dirus and Anopheles minimus

Abstract Background: The complexity of mosquito-borne diseases poses a major challenge to global health efforts to miti- gate their impact on people residing in sub-tropical and tropical regions, to travellers and deployed military person- nel.

Study protocol for a cluster-randomized split-plot design trial to assess the effectiveness of targeted active malaria case detection among high-risk populations in Southern Lao PDR (the AcME-Lao study)

Abstract Introduction: Novel interventions are needed to accelerate malaria elimination, especially in areas where asymptomatic parasitemia is common, and where transmission generally occurs outside of village-based settings. Testing of community members linked to a person with clinical illness (reactive case detection, RACD) has not shown effectiveness in prior studies due to the limited sensitivity of current point-of-care tests.

FluSense: A Contactless Syndromic Surveillance Platform for Influenza-Like Illness in Hospital Waiting Areas

Abstract: We developed a contactless syndromic surveillance platform FluSense that aims to expand the current paradigm of influenza-like illness (ILI) surveillance by capturing crowd-level bio-clinical signals directly related to physical symptoms of ILI from hospital waiting areas in an unobtrusive and privacy-sensitive manner.

Contact

  • (+1) 413-545-7426
  • 409 Arnold House • 715 N Pleasant Street, Amherst, MA 01003-9304
  • By appointment; COVID-19: Skype/Zoom
  • DM Me